$9.98
3.10% yesterday
NYSE, May 20, 10:00 pm CET
ISIN
US90240B1061
Symbol
TYRA
Sector
Industry

Tyra Bioscience Stock price

$9.98
+0.92 10.15% 1M
-5.89 37.11% 6M
-3.92 28.20% YTD
-8.74 46.69% 1Y
+0.52 5.50% 3Y
-16.02 61.62% 5Y
-16.02 61.62% 10Y
NYSE, Closing price Tue, May 20 2025
+0.30 3.10%
ISIN
US90240B1061
Symbol
TYRA
Sector
Industry

Key metrics

Market capitalization $529.84m
Enterprise Value $217.02m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.64
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-113.73m
Free Cash Flow (TTM) Free Cash Flow $-73.75m
Cash position $318.94m
EPS (TTM) EPS $-1.63
P/E forward negative
Short interest 12.04%
Show more

Is Tyra Bioscience a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Tyra Bioscience Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Tyra Bioscience forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a Tyra Bioscience forecast:

Buy
100%

Financial data from Tyra Bioscience

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs 0.54 0.54
38% 38%
-
-0.54 -0.54
38% 38%
-
- Selling and Administrative Expenses 25 25
39% 39%
-
- Research and Development Expense 87 87
27% 27%
-
-113 -113
29% 29%
-
- Depreciation and Amortization 0.54 0.54
38% 38%
-
EBIT (Operating Income) EBIT -114 -114
29% 29%
-
Net Profit -96 -96
28% 28%
-

In millions USD.

Don't miss a Thing! We will send you all news about Tyra Bioscience directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Tyra Bioscience Stock News

Neutral
PRNewsWire
8 days ago
CARLSBAD, Calif. , May 12, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that management will participate in the following investor conferences: Bank of America Global Healthcare Confer...
Neutral
PRNewsWire
12 days ago
- BEACH301 study of TYRA-300 for Pediatric Achondroplasia (ACH) Open for Enrollment - - Initiated patient dosing in SURF431 study of TYRA-430 for hepatocellular carcinoma (HCC) - - Cash, cash equivalents, and marketable securities of $318.9 million at Q1 2025; runway through at least 2027 - CARLSBAD, Calif. , May 8, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage bi...
Neutral
PRNewsWire
about 2 months ago
- Three INDs cleared by US FDA for TYRA's proprietary precision small molecules - - TYRA-300 to be evaluated in three Phase 2 studies: SURF302 for Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC), BEACH301 for pediatric achondroplasia (ACH) and SURF301 for metastatic urothelial cancer (mUC) - - Cash, cash equivalents, and marketable securities of $341.4 million at YE 2024; runway...
More Tyra Bioscience News

Company Profile

Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. Its proprietary in-house discovery platform, SNÅP, enables the rapid and precise refinement of structural design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA is developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor (FGFR) family members, which are altered in approximately 7% of all cancers. The company was founded by Daniel Bensen and Todd Harris on August 2, 2018 and is headquartered in Carlsbad, CA.

Head office United States
CEO Todd Harris
Employees 60
Founded 2018
Website www.tyra.bio

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today